NVP-LC2767, a dual consortium LBP of L. plantarum LC27 and B. longum LC67, was exclusively selected using NVP Healthcare’s DUOBIOME® technology. Preclinical and clinical studies demonstrated its safety and efficacy in both non-alcoholic and alcoholic subjects with fatty liver disease.

NVP-NK4146, a dual consortium LBP of L. mucosae NK41 and B. longum NK46, was exclusively selected using NVP Healthcare’s DUOBIOME® technology. Preclinical and clinical studies demonstrated its safety and efficacy, including alleviation of cognitive decline, reduction of amyloid-β accumulation and inflammation, and increased BDNF expression.

NVP-NK3398, a dual consortium LBP of L. reuteri NK33 and B. adolescentis NK98, was exclusively selected using NVP Healthcare’s DUOBIOME® technology. Preclinical and clinical studies demonstrated its safety and physiological efficacy, including improvements in mental health and sleep quality.

·Modulation of nose immunity(·Significant improvement in TNSS (total, rhinorrhea, nasal congestion) ·Significant improvement in NSDS (total, rhinorrhea) ·Significant improvement in RCAT (watery eyes and sleep disturbances, etc) ·Improvement in runny and stuffy nose ·10 billion CFU guaranteed ·Dual care (simultaneously cares for the nose and gut)

·Improvement in liver function (·Confirmation of the improvement on non-alcoholic / alcoholic fatty liver · Significant improvement on hepatic enzymes in blood (ALT, AST, γGTP)) · Significant decrease in the production of endotoxins (LPS) in feces and blood ·10 billion CFU guaranteed ·Dual care (simultaneously cares for the liver and gut)